You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康方生物(09926.HK)股價升逾一成 首個雙抗ADC藥物臨牀入組
康方生物(09926.HK)今日高開2.16%,最高見103.9元。現報102.9元,升10.88%,成交1,853.39萬股,涉資18.41億元。 近日,康方生物宣佈,公司自主研發的首個雙抗ADC藥物AK146D1(Trop2/Nectin4 ADC),治療晚期實體瘤的Ia期臨牀研究完成首例受試者入組。 AK146D1是康方生物首個進入臨牀階段的雙抗ADC藥物。 目前,AK146D1已成功獲得美國食品藥物管理局(FDA)、澳洲藥品管理局(TGA)和中國藥品監督管理局批準進行臨牀試驗。 目前,康方生物自主研發的全球首創雙抗新藥卡度尼利(PD-1/CTLA-4雙抗)和依沃西(PD-1/VEGF雙抗)均已獲批上市,且在全球範圍內開展了一系列領先療法佈局。該公司是全球唯一擁有2個腫瘤免疫療法(IO)雙抗的企業,已在IO+ADC全球大浪潮中建立了腫瘤免疫端顯着的全球領先優勢。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account